Genesis MedTech Completes Enrollment in its United States Early Feasibility Study Utilizing the J-Valvetm Transfemoral System for Patients with Severe Aortic Regurgitation

JC Medical reports milestone accomplishment with its TAVR device

BURLINGAME, Calif., Feb. 5, 2024 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced the completion of enrollment in its United States Early Feasibility Study (EFS) using its dedicated transcatheter aortic valve replacement (TAVR) system, J-Valvetm Transfemoral (TF) System. Finalizing the EFS marks another significant milestone for Genesis MedTech and its U.S.-based subsidiary JC Medical.

The FDA approved EFS trial involved patient enrollment at five centers across the United States. The trial focused on evaluating symptomatic individuals with severe Aortic Regurgitation. The last patient was successfully enrolled by Drs. Ron Waksman and Lowell Satler, MedStar Washington Hospital Center, Washington, DC. The EFS Co-Principal Investigators were Dr. Dean Kereiakes, President of the Christ Hospital Heart and Vascular Institute, Cincinnati, OH. and Dr. Michael Reardon, Professor of Cardiothoracic Surgery, Allison Family Distinguished Chair of Cardiovascular Research at Houston Methodist Hospital, Houston, TX. Patients meeting the inclusion criteria received treatment using the J-Valvetm TF system. The outcomes of this clinical experience will be presented later this year.

"TAVR has proven results for patients with Aortic Stenosis. An unmet need remains for patients with Aortic Regurgitation," Dr. Reardon commented. "The J-Valvetm being a dedicated TAVR design has shown promise in treating patients with aortic regurgitation. We are pleased with our findings to date from our EFS and look forward to the successful initiation of the pivotal trial."

Developed by JC Medical, the J-Valvetm TF System has been granted Breakthrough Device designation for the proposed indication of treating severe native aortic regurgitation (AR) and AR-dominant mixed aortic valve disease. Patients are assessed by a heart team to be eligible for the device and at high risk for surgical aortic valve replacement. The procedure is performed through a minimally invasive transfemoral approach, without the need for open-heart procedure or extracorporeal circulation. The innovative design and features of the J-Valvetm TF System can potentially help patients that suffer from aortic valve regurgitation, currently lacking approved treatment options in the United States.

"This accomplishment would not have been possible without the dedicated efforts of the investigators and research teams involved," stated Dr. Mark A. Turco, CEO of JC Medical and President of Vascular Intervention North America at Genesis MedTech. "We look forward to the data and learnings as well as the initiation of our upcoming Pivotal Trial."

The J-Valve tm TF System is an investigational device in the United States and Canada.

ABOUT GENESIS MEDTECH & JC MEDICAL

Based in Burlingame California, JC Medical Inc., under Genesis MedTech Group, is a transcatheter based cardiovascular company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases.

Genesis MedTech Group is a medical device company headquartered in Singapore. Founded by a group of professionals and entrepreneurs with MedTech experience globally, the company's product portfolio focuses on multi-therapy medical device products for emerging markets with sales and distribution through its established commercial network. Genesis MedTech Group covers the entire industry value chain of research and development, production, quality management, supply chain, marketing, and sales.

For more information, visit http://www.genesismedtech.com & https://j-valve.com

SOURCE Genesis MedTech